Physician profile
John Dixon
NPI 1316040413
$1,787.37
in general payments reported to CMS, 2019-2025
32 companies · $18.17 in 2025
The $18.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $375 · 2021: $434 · 2022: $248 · 2023: $145 · 2024: $74.38 · 2025: $18.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $245.70 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $216.81 | 2019-2025 | |
| Abbvie INC. | $194.35 | 2021-2022 | |
| Pfizer INC. | $116.82 | 2019-2023 | |
| Lilly USA, LLC | $81.38 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.51 | 2020-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $74.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $67.67 | 2019-2024 | Breztri |
| Otsuka America Pharmaceutical, INC. | $67.19 | 2022-2023 | Rexulti |
| Ironwood Pharmaceuticals, INC | $65.90 | 2021-2023 | Linzess |
| Amarin Pharma, INC. | $56.74 | 2019-2021 | |
| Novo Nordisk INC | $55.87 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.34 | 2019 | |
| Amgen INC. | $35.90 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $33.66 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.71 | 2021 | |
| Boston Scientific Corporation | $27.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $26.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.33 | 2021 | |
| Abbott Laboratories | $24.43 | 2021 | |
| Nevro Corp. | $23.62 | 2024 | Senza |
| Sunovion Pharmaceuticals INC. | $22.91 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.92 | 2022 | |
| Mylan Specialty L.P. | $20.10 | 2019 | |
| Allergan, INC. | $18.46 | 2019 | |
| Seqirus USA INC | $16.54 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Daiichi Sankyo INC. | $16.06 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.32 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.92 | 2021 | |
| Eisai INC. | $14.44 | 2021 | |
| Genentech USA, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.